Cytotoxic CD4+ T cells associated with the expression of major histocompatibility complex class II antigen of mouse myeloma cells secreting interferon-γ are cytolytic in vitro and tumoricidal in vivo

Cancer Gene Therapy

Volumn 5, Issue 5, 1998, Pages 313-320

  Xiang, Jim ^a,c   Moyana, Terence ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c Saskatoon Cancer Center   (Canada)

Author keywords

CD4+ T lymphocytes; IFN ; MHC class II antigen; Tumor vaccination

Indexed keywords

GAMMA INTERFERON; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CARCINOGEN TESTING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CULTURE; GENETICS; IMMUNOLOGY; METABOLISM; MOUSE; MULTIPLE MYELOMA; RAT; SECRETION;

ANIMALS; CARCINOGENICITY TESTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; RATS; TUMOR CELLS, CULTURED;

EID: 0032150753     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. De Maeyer E, De Maeyer-Guignard J. Interferons and Other Regulatory Cytokines. New York: John Wiley and Sons, Inc.; 1988.
2. Ros F, Cochet M, Fellous M. Interferon and major histocompatibility complex genes: a model to analyze eukaryotic gene regulation. In: Gresser I, ed. Interferon-γ. London: Academic Press Inc.; 1986:47-87.
3. Schwartz R, Momburg F, Moldenhauer G, Dorken B, Schirrmacher V. Induction of HLA class II antigen expression on human carcinoma cell lines by IFN-γ. Int J Cancer. 1985;35:245-252.
4. Fady C, Gardner A, Gera J, Lichtenstein A. Interferoninduced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: selective effects on HER2/neu expressing cells. Cancer Res. 1992;52:764-769.
5. Tanaka K, Isselbacher K, Khoury G, Jay G. Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science. 1985;228:26-29.
6. Greiner J, Guadagni F, Noguchi P, Pestka S, Colcher D, Fisher P, Schlom J. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987;235:895-898.
7. Kantor J, Tran R, Greiner J, Pestka S, Fisher P, Shively J, Schlom J. Modulation of carcinoembryonic antigen messenger RNA levels in human colon carcinoma cells by recombinant human γ-interferon. Cancer Res. 1989;49: 2651-2655.
8. Adams D, Hamilton T. Molecular transduction mechanisms by which IFN-gamma and other signals regulate macrophage development, Immunol Rev. 1987;97:5-19.
9. Weigent D, Stanton J, Johnson H. Recombinant gamma interferon. Biochem Biophys Res Commun. 1983;111:525-529.
10. Sone S, Utsugi T, Ogura T. Differential effects of recombinant interferon alpha, beta and gamma on induction of human lymphokine-activated killer activity. J Natl Cancer Inst. 1988;80:425-431.
11. Kurzrock R. Interferon gamma. In: Galvani DW, Cawley JC, eds. Cytokine Therapy. Cambridge, England: Cambridge University; 1992:131-151.
12. Watanabe Y, Kuribayashi K, Miyatake S, Nishihara K, Nakayama E, Taniyama T, Sakata T. Exogenous expression of mouse interferon gamma cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity. Proc Natl Acad Sci USA. 1989;86:9456-9460.
13. Restifo N, Spiess P, Karp S, Mule J, Rosenberg S. A nonimmunogenic sarcoma transduced with the cDNA for interferon elicits CD8 T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med. 1992;175:1423-1431.
14. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820-7825.
15. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of IL-2, IL-4, IL-7 TNF or IFN-γ. Proc Natl Acad Sci USA. 1993;90:2774-2778.
16. Tuttle T, McCrady C, Salour M, Bear H. IFN-γ plays a key role in T-cell-induced tumor regression. Cancer Res. 1993; 53:833.
17. Zoller M, Strubel A, Hammerling G, Raz A, Ben-Ze'ev A. IFN-γ treatment of B16 melanoma cells: opposing effects for non-adaptive immune defense and its reflection by metastatic spread, Int J Cancer. 1988;41:256-261.
18. Weber J, Rosenberg S. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro. Cancer Res. 1988;48:5818.
19. DeJong R, Stokkers E, Lamme J, Kool F, Borst M, Miedema F, VanLier R. Regulation of T-cell differentiation by CD2 and CD28 accessory molecules. Immunology. 1991;74:175-181.
20. Pace J, Russel B, Torres H, Johnson H, Gray P. Recombinant mouse IFN-γ induces the prime step in macrophage activation for tumor cell killing. J Immunol. 1983;130:2011.
21. Columbo M, Modesti G, Parmiani G, Forni G. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyte-T lymphocyte cross-talk. Cancer Res. 1992;52:4852-4857.
22. Siegel J. Effects of IFN-γ on the activation of human T lymphocytes. Cell Immunol. 1988;111:461.
23. Shimizu Y, Iwatsuki R, Herberman R, Whiteside T. Effects of cytokines on in vitro growth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother. 1991;32:280.
24. Tyring S, Klimpel W, Fleischman W, Baron S. Direct cytolysis by partially purified preparations of immune IFN. Int J Cancer. 1982;30:59.
25. Ratliff T, Kadmon A, Shapiro A, Jacobs A, Heston W. Inhibition of mouse bladder tumor proliferation by murine IFN-γ and its synergism with INF-β. Cancer Res. 1984;44: 4377-4384.
26. Teramura Y, Watanabe Y, Kan N, Masuda T, Kuribayashi K. IFN-γ producing tumor induces host tumor-specific T cell responses. Jpn J Cancer Res. 1993;84:689-696.
27. + MHC class II-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Immunol. 1995;154:4613-4622.
28. Xiang J, Qi Y, Chen Y, Moyana T. Targeting gamma interferon to tumor cells by a genetically engineered bifunctional fusion protein RM4/IFN-y. Hum Antib Hybrid. 1996;7:2-10.
29. Qi Y, Chen Y, Xiang J. Mouse myeloma cell line secreting fusion protein RM4/IFN-γ elicits antitumor CD8 MHC class I-restricted T cells that are cytolytic in vitro and tumoricidal in vivo. J Interferon Cytokine Res. 1996;16:771-776.
30. Qi Y, Moyana T, Chen Y, Xiang J. Characterization of anti-tumor immunity derived from the inoculation of myeloma cells secreting the fusion protein RM4/IFN-γ. Hum Antib Hybrid. 1996;7:21-26.
31. Xiang J, Moyana T, Kaira J, Hamilton T, Qi Y. Construction and characterization of a high-affinity chimeric anti-colorectal carcinoma antibody ccM4. Mol Biother. 1992;4:174-182.
32. Hellstrom K, Hellstrom I. Principles of tumor immunity: tumor antigen. In: Delvita V, Hellman S, and Rosenberg S, eds. The Biologic Therapy of Cancer. Philadelphia: J.B. Lippincott Co.; 1991:35.
33. Greenberg P. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol. 1991;49:281-289.
34. + T lymphocytes. J Immunol. 1991;146:3242-3249.
35. + T lymphocyte-induced target cell detachment: a model for T cell-mediated lytic and nonlytic inflammatory processes. J Immunol. 1991;146: 405-413.
36. + human cytotoxic T cell clones. Clin Immunol Immunopathol. 1996;78:70-76.
37. Gansbacher B, Houghton A, Livingston P, Minasian L, Rosenthal F, Gilboa E, Golde D, Oettgen H, Syeffens T, Yang S, Wong G. A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete IL-2 in patients with metastatic melanoma. Hum Gene Ther. 1992;3:677-690.
38. Gansbacher B, Motzer R, Houghton A, Bander N, Minasian L, Rosenthal F, Gilboa E, Scheinfeld J, Yang S, Wong G, Golde D, Reuter V, Livingston P, Nanus D, Fair W. A pilot study of immunization with IL-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Hum Gene Ther. 1992;3:691-703.